Literature DB >> 17670804

Medication and treatment use in primary care patients with chronic pain of predominantly neuropathic origin.

Nicola Torrance1, Blair H Smith, Margaret C Watson, Michael I Bennett.   

Abstract

BACKGROUND: Neuropathic pain is widely recognized as one of the most difficult pain syndromes to treat and presents a significant challenge for pain clinicians and GPs.
METHODS: The Self-complete Leeds Assessment of Neuropathic Symptoms and Signs (S-LANSS) questionnaire, recently validated for identifying pain of predominantly neuropathic origin (POPNO), was sent to 6000 adults identified from general practices in the UK. The questionnaire also contained items about chronic pain identification, medications and treatments received for pain and the pain relief these provided.
RESULTS: In total, 1420/3002 (48%) of respondents indicated that they suffered with any chronic pain. These were further categorized as those with chronic pain who were S-LANSS negative ['chronic pain (non-POPNO)' group, n = 1179] and those with chronic pain who were S-LANSS positive, indicating the presence of POPNO ('chronic POPNO' group, n = 241). Questions relating to treatments and medications were completed by 88% of the respondents (1244/1420). The chronic POPNO group was more likely to receive multiple pain medications (37% versus 21% took two or more pain medications, P < 0.001) and stronger painkillers [e.g. opioids odds ratio 1.94; 95% confidence interval 1.10, 3.42]. Despite this, they reported less effective pain relief than the non-POPNO chronic pain group.
CONCLUSION: Patients in primary care reporting chronic pain were found generally to obtain incomplete relief from their medication with chronic POPNO patients reporting less relief. It is important that patients with any chronic pain are identified and managed appropriately according to their distinct treatment needs.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17670804     DOI: 10.1093/fampra/cmm042

Source DB:  PubMed          Journal:  Fam Pract        ISSN: 0263-2136            Impact factor:   2.267


  24 in total

Review 1.  Pharmacologic management of chronic neuropathic pain: Review of the Canadian Pain Society consensus statement.

Authors:  Alex Mu; Erica Weinberg; Dwight E Moulin; Hance Clarke
Journal:  Can Fam Physician       Date:  2017-11       Impact factor: 3.275

Review 2.  Institutional animal care and use committee considerations for animal models of peripheral neuropathy.

Authors:  Thea Brabb; Larry Carbone; Jessica Snyder; Nona Phillips
Journal:  ILAR J       Date:  2014

3.  Pharmacologic management of chronic pain.

Authors:  Hue Jung Park; Dong Eon Moon
Journal:  Korean J Pain       Date:  2010-05-31

4.  Prevalence and characterization of neuropathic pain in a primary-care setting in Spain: a cross-sectional, multicentre, observational study.

Authors:  Concepción Pérez; María Teresa Saldaña; Ana Navarro; Inma Vilardaga; Javier Rejas
Journal:  Clin Drug Investig       Date:  2009       Impact factor: 2.859

5.  Neuropathic Pain Among Community-Dwelling Older People: A Clinical Study in Finland.

Authors:  Susanna Rapo-Pylkkö; Maija Haanpää; Helena Liira
Journal:  Drugs Aging       Date:  2015-09       Impact factor: 3.923

6.  Using Analgesics for Emotional Modulation is Associated With Increased Distress, Depression, and Risk of Opioid and Alcohol Misuse: Initial Evaluation and Component Analysis of the Reasons for Analgesic Use Measure (RAUM).

Authors:  Kevin E Vowles; Robert W Bailey; Mindy L McEntee; Melissa Pielech; Karlyn A Edwards; Lena A Bolling; W Evan Rivers
Journal:  Clin J Pain       Date:  2018-10       Impact factor: 3.442

7.  The monoacylglycerol lipase inhibitor KML29 with gabapentin synergistically produces analgesia in mice.

Authors:  Molly S Crowe; Catheryn D Wilson; Emma Leishman; Paul L Prather; Heather B Bradshaw; Matthew L Banks; Steven G Kinsey
Journal:  Br J Pharmacol       Date:  2017-11-20       Impact factor: 8.739

Review 8.  Neuropathic pain: quality-of-life impact, costs and cost effectiveness of therapy.

Authors:  Alec B O'Connor
Journal:  Pharmacoeconomics       Date:  2009       Impact factor: 4.981

9.  Fe3O4@Polydopamine-Labeled MSCs Targeting the Spinal Cord to Treat Neuropathic Pain Under the Guidance of a Magnetic Field.

Authors:  Meichen Liu; Weijia Yu; Fuqiang Zhang; Te Liu; Kai Li; Meng Lin; Ying Wang; Guoqing Zhao; Jinlan Jiang
Journal:  Int J Nanomedicine       Date:  2021-05-11

10.  Pregabalin, celecoxib, and their combination for treatment of chronic low-back pain.

Authors:  Carlo Luca Romanò; Delia Romanò; Cristina Bonora; Giuseppe Mineo
Journal:  J Orthop Traumatol       Date:  2009-11-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.